CCNB1 and cervical carcinoma: Furthermore, Juan Wei et al.’s study on cervical cancer cells demonstrated that isorhamnetin effectively hindered cell cycle progression at the initial G2/M phase by suppressing protein expressions of cyclin B1, cell division cycle 25C (Cdc25C), and Cdc2 (29).